SI-BONE(US:SIBN)2022-05-09 21:06Market Opportunity & Leadership - SI-BONE addresses a large market with a $2.5 billion annual U S opportunity in SI joint fusion[7, 24] - The company has performed over 65,000 procedures worldwide using iFuse Technology[7, 19, 74] and has a majority estimated U S market share in iFuse[7] - The company estimates a ~$250 million Adult Spinal Deformity market opportunity[15] Clinical & Technological Advantages - iFuse demonstrates 6x resistance compared to SI screws and 3x strength compared to standard 8 0mm cannulated screws[37] - The SALLY Prospective Clinical Trial of iFuse-3D showed a 57-point improvement in VAS Pain Reduction and a 25-point improvement in ODI Disability[48] - The company has secured 61 issued patents and 44 pending patents, with iFuse patents covering until November 2024 and iFuse-3D patents covering until September 2035[38] Financial Performance & Growth Strategy - SI-BONE's worldwide revenue for the first quarter of 2022 was $22.4 million[17] - The company achieved a gross margin of approximately 87% in the first quarter of 2022[17, 67] - The company anticipates revenue between $106 million and $108 million for the full year 2022, representing an implied growth of 18%-20%[64]